Boehringer Ingelheim GmbH has cut its US sales staff for Cyltezo (adalimumab), the first interchangeable biosimilar rival to AbbVie Inc.’s Humira to be launched in the US, as it and other biosimilar versions continue to struggle in the US.
Figures from the end of last year demonstrated the limited impact made by Humira rivals since the launch of an...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?